目的：本研究的目的是描述左西孟旦（无负荷剂量）对血流动力学的影响，肌力药/血管加压药，急性心力衰竭（AHF）的死亡率。
方法：对接受左西孟旦治疗AHF的患者进行分析。左西孟旦剂量，血液动力学数据,强迫症/血管加压药要求，和开始前的流体平衡，在结束时，24小时后收集左西孟旦。死亡率也有报道。
结果：对87例患者进行分析。平均左西孟旦剂量（无负荷）为每分钟0.096μg/kg（±0.014），和平均持续时间，26(±7.2)小时。心率没有变化(开始，post,和24小时后）（92[±19]，92[±26]，和92[±15]）或平均动脉压（69[±10]，72[±8]，和72[±10]mmHg，分别)。在之前和之后24小时，多巴酚丁胺的中位数从每分钟7.27降至0μg/kg，去甲肾上腺素从每分钟0.20降至0.1μg/kg。平均心脏指数从每平方米2.38±0.0.72显着增加至2.98±0.0.77L/min，灌注标志物显着增加：碱过量从-2.77至0.39mmol/L，输注前和输注后24小时，乳酸为2.1至1.4mmol/L。生存率为53%。
结论：左西孟旦，没有负荷剂量，改善心脏指数和灌注，同时降低AHF患者的肌力/血管加压药需求。
OBJECTIVE: The purpose of this study is to describe the effect of levosimendan (without loading dose) on hemodynamics, inotropes/vasopressors, and mortality in acute heart failure (AHF).
METHODS: Patients who received levosimendan for AHF were analyzed. Levosimendan dose, hemodynamic data, inotrope/vasopressor requirements, and fluid balance before commencement, at conclusion of, and 24 hours after levosimendan were collected. Mortality is also reported.
RESULTS: Eighty-seven patients were analyzed. The mean levosimendan dose (without loading) was 0.096 μg/kg per minute (±0.014), and mean duration, 26 (±7.2) hours. There was no change in heart rate (start, post, and 24 hours post) (92 [±19], 92 [±26], and 92 [±15]) or mean arterial pressure (69 [±10], 72 [±8], and 72 [±10] mm Hg, respectively). There was a significant reduction in median dobutamine from 7.27 to 0 μg/kg per minute and noradrenaline from 0.20 to 0.1 μg/kg per minute before and 24 hours after. There was a significant increase in both mean cardiac index from 2.38 ± 0.0.72 to 2.98 ± 0.0.77 L/min per square meter and in markers of perfusion: base excess from -2.77 to 0.39 mmol/L, and lactate from 2.1 to 1.4 mmol/L before and 24 hours after infusion. Survival was 53%.
CONCLUSIONS: Levosimendan, without a loading dose, improved cardiac index and perfusion while allowing a reduction in inotropic/vasopressor requirements in patients with AHF.
PDF(Sci-hub)